TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats-Reference-Cited by-同舟云学术

TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats

Published:2022-08 Issue: Volume:145 Page:107017
ISSN:1537-1891
Container-title:Vascular Pharmacology
language:en
Short-container-title:Vascular Pharmacology

Author:

Zhao Congke,Hu Liqing,He Xiangrong,Li Lijun,Yin Minghui,Tettey Abraham Terkpertey,Wang Yu,Shen Jingshan,Tang Siyuan,Wu Chunhui,Li Qianbin,Wang Zhen,Li Xiaohui

Publisher

Elsevier BV

Subject

Pharmacology,Molecular Medicine,Physiology

Reference42 articles.

1. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives;Humbert;Eur. Respir. J.,2019

2. Haemodynamic definitions and updated clinical classification of pulmonary hypertension;Simonneau;Eur. Respir. J.,2019

3. A global view of pulmonary hypertension;Hoeper;Lancet Respir. Med.,2016

4. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

5. Targeted drugs for treatment of pulmonary arterial hypertension: past, present, and future perspectives;Zheng;J. Med. Chem.,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allosteric site identification, virtual screening and discovery of a sulfonamide Hsp110-STAT3 interaction inhibitor for the treatment of hypoxic pulmonary arterial hypertension;European Journal of Medicinal Chemistry;2024-12

2. Discovery and Optimization of Hsp110 and sGC Dual-Target Regulators for the Treatment of Pulmonary Arterial Hypertension;Journal of Medicinal Chemistry;2024-07-26

3. Inhibition of Hsp110-STAT3 interaction in endothelial cells alleviates vascular remodeling in hypoxic pulmonary arterial Hypertension model;Respiratory Research;2023-11-17

4. Avanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF-κB-NLRP3 Inflammasome Signaling Pathway;Lung;2022-08-30

5. Potential diabetic cardiomyopathy therapies targeting pyroptosis: A mini review;Frontiers in Cardiovascular Medicine;2022-08-18